These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35495226)

  • 1. Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1.
    Niu X; Nong S; Zhang X; Li X; Wang C; Li W; Zhou T
    RSC Adv; 2020 Jan; 10(8):4725-4732. PubMed ID: 35495226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites.
    Wang M; Yao P; Gao M; Jin J; Yu Y
    RSC Adv; 2020 Feb; 10(14):8044-8053. PubMed ID: 35497855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering an enhanced thrombin-based GLP-1 analog with long-lasting glucose-lowering and efficient weight reduction.
    Pan H; Xie Y; Lu W; Chen Y; Lu Z; Zhen J; Wang W; Shang A
    RSC Adv; 2019 Sep; 9(53):30707-30714. PubMed ID: 35529389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel mono-PEGylated dimeric GLP-1 conjugate with enhanced receptor activation and prolonged anti-diabetes efficacies.
    Li P; Zhang J; Jia Y; Zhang Y
    Life Sci; 2020 Aug; 254():117752. PubMed ID: 32387412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel peptidic dual GLP-1/glucagon receptor agonist alleviates diabetes and diabetic complications in combination with low-intensity ultrasound.
    Ding WX; Wang HY; Peng LJ; Zhang F; Yuan S; Zhao LH
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12423-12436. PubMed ID: 33336763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and evaluation of GLP-1 receptor G-protein biased agonist with prolonged efficacy on diabetes.
    Zhou P; Jiang X; Li X
    Life Sci; 2021 Jul; ():119844. PubMed ID: 34293397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals.
    Wu Y; Ji T; Lv J; Wang Z
    Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors.
    Huang P; Meng L; Tan J; Gu X; Huang M; Huang F; Ma R; Wang J
    Life Sci; 2021 Apr; 270():119136. PubMed ID: 33508289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lithocholic Acid-Based Peptide Delivery System for an Enhanced Pharmacological and Pharmacokinetic Profile of Xenopus GLP-1 Analogs.
    Han J; Chen X; Zhao L; Fu J; Sun L; Zhang Y; Zhou F; Fei Y
    Mol Pharm; 2018 Jul; 15(7):2840-2856. PubMed ID: 29799205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents.
    Yang Q; Zhou F; Tang X; Wang J; Feng H; Jiang W; Jin L; Jiang N; Yuan Y; Han J; Yan Z
    Eur J Med Chem; 2022 Apr; 233():114214. PubMed ID: 35231829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design and evaluation of GLP-1 derivative for treating hyperglycemia combined with overexercise-induced myocardial injury.
    Wang Y; Xia Z; Xie H; Dong J
    Life Sci; 2021 May; 272():119030. PubMed ID: 33453242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications.
    Xu S; Wang F; Li H; Wang Y; Fang D
    Bioengineered; 2022 Mar; 13(3):4621-4633. PubMed ID: 34696658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects.
    Zhong X; Chen Z; Chen Q; Zhao W; Chen Z
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30795583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everestmab, a novel long-acting GLP-1/anti GLP-1R nanobody fusion protein, exerts potent anti-diabetic effects.
    Pan H; Su Y; Xie Y; Wang W; Qiu W; Chen W; Lu W; Lu Z; Wang W; Shang A
    Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):854-866. PubMed ID: 32468873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and characterization of novel oxyntomodulin derivatives with potent dual GLP-1/glucagon receptor activation and prolonged antidiabetic effects.
    Pei Z; Zhou D; Yan J; Wang S; Yang X; Pei Z
    Life Sci; 2020 Jul; 253():117651. PubMed ID: 32304764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
    Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
    Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
    Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
    Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes.
    Moffett RC; Patterson S; Irwin N; Flatt PR
    Diabetes Metab Res Rev; 2015 Mar; 31(3):248-55. PubMed ID: 25256010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.